Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$11.27 USD
+0.23 (2.08%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $11.05 -0.22 (-1.95%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Brokerage Reports
Dynavax Technologies Corporation [DVAX]
Reports for Purchase
Showing records 101 - 120 ( 124 total )
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
No Surprises in HEPLISAV Data Presentation at ICAAC; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Life Sciences MAC Best Ideas Conference - New York City - August 16 & 17, 2011 Day 2 - Key Takeaways
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Topline Phase III HEPLISAV Data and Q2:2011 Financials
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Data From First Phase III HEPLISAV Study Expected Within 8 Weeks
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Q1:2011 Financial Recap; Expect Phase III HEPLISAV Data in Mid-2011
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Assuming Coverage with OUTPERFORM and Lowering Fair Value to $6 from $9; Optimistic on HEPLISAV
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Pipeline Progress: Universal Flu Vaccine and Hepatitis B Therapeutic Vaccine
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Heplisav Passes 4th DSMB Safety Review; Raising PT to $9
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Biotechnology / Biopharmaceuticals - Potential Q1:11 Movers
Provider: WEDBUSH SECURITIES INC.
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Potential Q1:11 Movers
Provider: WEDBUSH SECURITIES INC.
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
2010 AASLD Abstract Titles Review - Second Wave Including Late-Breakers
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Life Sciences -MAC Best Ideas Conference - Key Takeaways New York City.
Provider: WEDBUSH SECURITIES INC.
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Q2 Earnings Non-Event; Awareness on the Rise as Phase III Data Release Draws Near.
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Heplisav Studies on Track; Nature Publication Highlights Upside; Reiterate OP.
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y